Sionna Therapeutics(SION)
WALTHAM, MABiotechnology
Focus: Sionna Therapeutics is a public biotech company focused on small-molecule therapeutics targeting cystic fibrosis, a rare genetic disease with significant unmet medical need. The company is early-stage with two programs in Phase 1 and Phase 2 development.
Profile data last refreshed 9h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Sionna Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Sionna Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SION-451
Cystic Fibrosis (CF)Clinical Trials (1)
NCT07035990Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
Phase 1Help build intelligence for Sionna Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.